Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction.

ABSTRACT: Myocardial infarction (MI) accelerates immune ageing characterised by lymphopenia, expansion of terminally differentiated CD8⁺ T-lymphocytes (CD8⁺ T_EMRA) and inflammation. Pre-clinical data showed that TA-65, an oral telomerase activator, reduced immune ageing and inflammation after MI. We conducted a double blinded randomised controlled pilot trial evaluating the use of TA-65 to reduce immune cell ageing in patients following MI. Ninety MI patients aged over 65 years were randomised to either TA-65 (16 mg daily) or placebo for 12 months. Peripheral blood leucocytes were analysed by flow cytometry. The pre-defined primary endpoint was the proportion of CD8⁺ T-lymphocytes which were CD8⁺ T_EMRA after 12 months. Secondary outco

SUBMITTER: Bawamia B 

PROVIDER: S-EPMC10122201 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature